Skip to main content

Table 5 Significantly modified proteins in post treated budesonide versus pre treated budesonide asthmatics

From: Network analysis of quantitative proteomics on asthmatic bronchi: effects of inhaled glucocorticoid treatment

Swiss Prot Acc. No. Symbol Entrez Gene Name Fold Change Location Protein Class
P01023 A2M alpha-2-macroglobulin -1.27 Extracellular space cytokine
P04075 ALDOA aldolase A, fructose-bisphosphate -1.22 Cytoplasm aldolase
P06576 ATP5B ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide -1.76 Cytoplasm ATP synthase
Q9BPU6 DPYSL5 dihydropyrimidinase-like 5 2.01 Cytoplasm hydrolase
P60866 RPS20 ribosomal protein S20 1.54 Cytoplasm ribosomal protein
P29508 SERPINB3 serpin peptidase inhibitor, clade B (ovalbumin), member 3 2.31 Extracellular space serine protease inhibitor
P08670 VIM vimentin -1.69 Cytoplasm structural protein
  1. © 2000-2011 Ingenuity Systems, Inc. All rights reserved.
  2. All listed proteins showed a statistically significant difference (p value < 0.05) between the groups using a Student's t-test. The fold change for each protein is calculated by dividing the average ratio of the budesonide post treated biopsy with the average ratio of the paired pre budesonide biopsy. The negative fold change indicates down regulation of protein expression after budesonide treatment, while the positive fold change indicates up regulation after budesonide treatment. The cell location of the protein is annotated by IPA. The protein class is determined using the PANTHER Classification System.